Haozhu Biotech: Intraocular Sodium Hyaluronate Cross-linked Gel Product Receives Medical Device Registration Certificate

2026-03-18 05:42:02

People’s Financial News, March 16 — Haohai Shengke (688366) announced on March 16 that its wholly-owned subsidiary, Qisheng Biological, recently received the Medical Device Registration Certificate from the National Medical Products Administration for an intraocular cross-linked sodium hyaluronate gel product. This product uses innovative molecular linear rearrangement cross-linking patented technology and is used to treat hole-induced retinal detachment. It is suitable for sealing retinal holes and is the company’s first product in the field of retinal treatment.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes